Product Name :
AN-2690
Description:
Tavaborole, also known as AN-2690 (trade name Kerydin) is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, Leucyl-tRNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects were observed in any of its clinical trials.
CAS:
174671-46-6
Molecular Weight:
151.93
Formula:
C7H6BFO2
Chemical Name:
5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol
Smiles :
OB1OCC2=CC(F)=CC=C21
InChiKey:
LFQDNHWZDQTITF-UHFFFAOYSA-N
InChi :
InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
Purity:
≥98% (or refer to the Certificate of Analysis)
Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis
Storage Condition :
Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.
Shelf Life:
≥360 days if stored properly.{{Imatinib} web|{Imatinib} Anti-infection|{Imatinib} Protocol|{Imatinib} Description|{Imatinib} supplier|{Imatinib} Epigenetic Reader Domain}
Stock Solution Storage:
0 – 4 oC for 1 month or refer to the Certificate of Analysis.
Additional information:
Tavaborole, also known as AN-2690 (trade name Kerydin) is a topical antifungal medication for the treatment of onychomycosis, a fungal infection of the nail and nail bed. Tavaborole began its Phase 3 trials in December 2010 and was approved in July 2014. Tavaborole inhibits an essential fungal enzyme, Leucyl-tRNA synthetase, or LeuRS, required for protein synthesis. The inhibition of protein synthesis leads to termination of cell growth and cell death, eliminating the fungal infection. No treatment-related systemic side effects were observed in any of its clinical trials.{{Luvixasertib} web|{Luvixasertib} Mps1|{Luvixasertib} Protocol|{Luvixasertib} Description|{Luvixasertib} custom synthesis|{Luvixasertib} Epigenetic Reader Domain} |Product information|CAS Number: 174671-46-6|Molecular Weight: 151.PMID:34235739 93|Formula: C7H6BFO2|Chemical Name: 5-fluoro-1,3-dihydro-2,1-benzoxaborol-1-ol|Smiles: OB1OCC2=CC(F)=CC=C21|InChiKey: LFQDNHWZDQTITF-UHFFFAOYSA-N|InChi: InChI=1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2|Technical Data|Appearance: Solid Power|Purity: ≥98% (or refer to the Certificate of Analysis)|Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis|Storage Condition: Dry, dark and -20 oC for 1 year or refer to the Certificate of Analysis.|Shelf Life: ≥360 days if stored properly.|Stock Solution Storage: 0 – 4 oC for 1 month or refer to the Certificate of Analysis.|Drug Formulation: To be determined|HS Tariff Code: 382200|Products are for research use only. Not for human use.|
